Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Kendrick

Vascular Surgery Columbia, TN Medical Doctor

NPI 1265621635 CMS profile 1083042

832 Westover Dr Ste 200, Columbia, TN 38401

Open in the dashboard

General payments

$15,598

279 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Kendrick of Columbia, TN is reported in the CMS Open Payments database as having received $15,598 across 279 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $508 22
2024 General $1,052 38
2023 General $595 35
2022 General $2,216 44
2021 General $1,126 53
2020 General $2,768 57
2019 General $7,333 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Kendrick
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to John Kendrick were reported at $508. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year John Kendrick Vascular Surgery median Middle half National median
2019 $7,333 $796 $226–$2,363 $163
2020 $2,768 $348 $118–$1,110 $114
2021 $1,126 $471 $158–$1,421 $132
2022 $2,216 $725 $222–$2,183 $149
2023 $595 $836 $257–$2,440 $160
2024 $1,052 $909 $252–$2,619 $164
2025 $508 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $6,354 9 payments
  2. Cardiovascular Systems Inc. $2,756 61 payments
  3. Bard Peripheral Vascular, Inc. $2,008 53 payments
  4. Philips Electronics North America Corporation $732 2 payments
  5. Silk Road Medical, Inc. $469 11 payments
  6. Penumbra, Inc. $377 20 payments
  7. Boston Scientific Corporation $273 12 payments
  8. Abbott Laboratories $263 17 payments
  9. Cordis US Corp. $235 13 payments
  10. Becton, Dickinson and Company $217 10 payments
  11. Other $1,914 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $8,763 9 payments
  2. Food and Beverage $6,835 270 payments
Products named General payments · program years 2019–2025
  1. IN.PACT Admiral $6,114 5 payments
  2. Diamondback Peripheral $1,891 31 payments
  3. Peripheral Orbital Atherectomy System $761 28 payments
  4. IGT D Peripheral $732 2 payments
  5. COVERA $324 9 payments
  6. ENROUTE 0.014 Guidewire $322 4 payments
  7. ENROUTE Transcarotid Stent System $322 4 payments
  8. ENROUTE Transcarotid Neuroprotection System $322 4 payments
  9. ENHANCE Transcarotid Peripheral Access Kit $322 4 payments
  10. Venovo $265 8 payments
  11. Other $5,057 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

566

Median for Vascular Surgery: 122

Drug cost

$109,411

Median for Vascular Surgery: $14,135

Branded share of claims

84.6%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 82 $76,386
Xarelto Rivaroxaban Brand 36 $28,528
Clopidogrel Clopidogrel Bisulfate Brand 308 $3,422
Atorvastatin Calcium Generic 16 $335
Cilostazol Generic 15 $310
Pravastatin Sodium Generic 27 $208
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 53 $130
Pantoprazole Sodium Generic 15 $79
Prednisone Generic 14 $13

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$825,867

Medicare's payments for the services billed

Medicare patients

671

Average age 74

Services billed

2,455

346 women, 325 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 44%
Ischemic heart disease 41%
Chronic kidney disease 41%
Heart failure 28%
COPD 27%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

279 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record